- Home
- SDGR vs TVTX Comparison
SDGR vs TVTX Comparison
Compare SDGR & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDGR
- TVTX
- Stock Information
- Founded
- SDGR 1990
- TVTX 2008
- Country
- SDGR United States
- TVTX United States
- Employees
- SDGR N/A
- TVTX N/A
- Industry
- SDGR Biotechnology: Pharmaceutical Preparations
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- SDGR Health Care
- TVTX Health Care
- Exchange
- SDGR Nasdaq
- TVTX Nasdaq
- Market Cap
- SDGR 1.6B
- TVTX 1.5B
- IPO Year
- SDGR 2020
- TVTX N/A
- Fundamental
- Price
- SDGR $19.00
- TVTX $18.37
- Analyst Decision
- SDGR Buy
- TVTX Buy
- Analyst Count
- SDGR 10
- TVTX 12
- Target Price
- SDGR $32.90
- TVTX $24.58
- AVG Volume (30 Days)
- SDGR 624.0K
- TVTX 1.2M
- Earning Date
- SDGR 02-26-2025
- TVTX 02-13-2025
- Dividend Yield
- SDGR N/A
- TVTX N/A
- EPS Growth
- SDGR N/A
- TVTX N/A
- EPS
- SDGR N/A
- TVTX N/A
- Revenue
- SDGR $193,348,000.00
- TVTX $203,447,000.00
- Revenue This Year
- SDGR N/A
- TVTX $62.38
- Revenue Next Year
- SDGR $26.50
- TVTX $57.65
- P/E Ratio
- SDGR N/A
- TVTX N/A
- Revenue Growth
- SDGR N/A
- TVTX 57.08
- 52 Week Low
- SDGR $16.67
- TVTX $5.12
- 52 Week High
- SDGR $33.63
- TVTX $20.33
- Technical
- Relative Strength Index (RSI)
- SDGR 43.08
- TVTX 52.05
- Support Level
- SDGR $18.63
- TVTX $16.80
- Resistance Level
- SDGR $20.20
- TVTX $18.76
- Average True Range (ATR)
- SDGR 1.00
- TVTX 0.90
- MACD
- SDGR -0.15
- TVTX 0.02
- Stochastic Oscillator
- SDGR 19.14
- TVTX 61.57
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.